Biotechs Rise on Bet Medivation Losers Will Look to Next DealBy , , and
BioMarin, Tesaro, Incyte, Clovis shares all gain Monday
Pfizer beat out Sanofi, others in $14 billion Medivation deal
For losers in the $14 billion bidding war over drugmaker Medivation Inc., the best cure for the mergers and acquisitions blues may be to go shopping.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.